

**Supplementary Table 1. Frequency of relapse MRI findings over the total of relapses**

	NMOSD (+)	NMOSD (-)	MOG-AD
STM	16 (12.5)	5 (5.1)	3 (11.1)
LETM	54 (42.9)	65 (58.9)	12 (46)
Optic nerve lesions	38 (30.4)	31 (28.2)	14 (55.6)
Area postrema lesions	2 (1.8)	3 (2.6)	-
Diencephalic lesions	2 (1.8)	3 (2.6)	-
Hemispheric white matter lesions	2 (1.8)	3 (2.6)	-
Other	2 (1.8)	-	-
Unknown	2 (1.8)	3 (2.6)	6 (22.2)

STM: short-segment transverse myelitis, LETM: longitudinally extensive transverse myelitis, NMOSD (+): AQP4-ab-positive NMOSD, NMOSD (-): AQP4-ab-negative NMOSD, MOG-AD: MOG-associated diseases.

**Supplementary Table 2. Long-term treatment of the studied cohort.**

		NMOSD (-) (N=45)	NMOSD (+) (N=75)	MOG-AD (N=11)
		N, (%)	N, (%)	N, (%)
First treatment	MMF	1 (2.2)	3 (4)	1 (9)
	Rituximab	7 (15.6)	17 (22.7)	2 (18.2)
	Azathioprine	27 (60)	46 (61.3)	3 (27.3)
	Other	3 (6.6)	1 (1.3)	1 (9)
	Untreated	7 (15.6)	6 (8)	4 (36.3)
Switched first treatment		17 (44.7)	28 (40.6)	-

Reason for interrupting first treatment	New relapse	8 (47)	14 (50)	1 (50)
	SE	1 (5.9)	4 (14.3)	-
	Other	8 (47)	10 (35.7)	1 (50)
Second treatment	MMF	1 (2.2)	2 (2.6)	-
	Rituximab	8 (17.8)	20 (26.6)	-
	Azathioprine	31 (69)	49 (65.3)	-
	Other	1 (2.2)	3 (4)	-
	Untreated	4 (8.8)	1 (1.3)	-
Switched second treatment		1 (11.1)	8 (30.7)	-
Current treatment	MMF	4 (8.9)	4 (5.3)	1 (9)
	Rituximab	13 (28.9)	38 (50.6)	6 (54.5)
	Azathioprine	23 (51.1)	29 (38.7)	3 (27.3)
	Other	1(2.2)	2 (2.7)	-
	Untreated	4 (8.9)	2 (2.7)	1 (9)

MMF: mycophenolate mofetil; SE: side effect.

**Supplementary table 3. Predictors of complete remission in NMOSD (positive and negative) patients from relapses**

	OR	95%CI	P
<b>Age at disease onset</b>	<b>2.27</b>	<b>2.11-4.12</b>	<b>0.002</b>
Female	0.57	0.12-2.52	0.461
Symptom at onset	0.77	0.43-1.23	0.862
Time from onset of relapse to start of treatment	0.95	0.82-1.56	0.885
Duration of long-term immunosuppressive treatment	0.88	0.65-1.65	0.421
First line treatment for relapse	1.03	0.67-1.78	0.223

**Supplementary table 4. Predictors of complete remission in MOG-AD patients from relapses**

	OR	95%CI	P
<b>Age at disease onset</b>	<b>1.56</b>	<b>1.22-2.01</b>	<b>0.03</b>
Female	0.54	0.34-2.13	0.237
Symptom at onset	1.12	0.34-3.12	0.652
Time from onset of relapse to start of treatment	1.29	0.65-2.65	0.126
Duration of long-term immunosuppressive treatment	0.96	0.23-3.14	0.17
First line treatment for relapse	-	-	-